Literature DB >> 7736405

Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.

A A Kasperlik-Załuska1, B M Migdalska, S Zgliczyński, A M Makowska.   

Abstract

BACKGROUND: Adrenocortical carcinoma is a rare tumor with a poor prognosis. This work was aimed at analyzing the clinical outlook and treatment results of 52 patients with this disease.
METHODS: This study included patients with adrenocortical carcinoma referred to the Department of Endocrinology at the Center of Postgraduate Medical Education (Warsaw, Poland) during the last 30 years. In 11 patients, the adrenal tumor was found incidentally by ultrasonographic scan. Hormonal examinations made it possible to define the endocrine activity of the tumors, whereas imaging techniques helped to determine their staging. Forty-eight patients underwent surgery, and 36 of them received mitotane. This drug was administered to 26 patients for a range of 10 months to 10 years; 13 patients received mitotane immediately after the operation, and 13 others after a delay. The patients with severe hypercorticism were pretreated before surgery with aminoglutethimide and mitotane.
RESULTS: The study comprised 10 men and 42 women; hormonally active tumors were diagnosed in 39 of them. Cushing's syndrome was the most frequent entity. At diagnosis, 17 cases were classified as localized disease, 15 as regional disease, and 20 as distant disease. Pretreatment with the inhibitors of steroidogenesis improved the survival perspectives in the early postoperative period. As of this writing, there were 12 survivors in the group of 26 patients treated by surgery and long term mitotane therapy and only 2 survivors of 7 patients treated with surgery only.
CONCLUSIONS: Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7736405     DOI: 10.1002/1097-0142(19950515)75:10<2587::aid-cncr2820751028>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  [Routine after-care 16 years after left adrenalectomy for adrenal cortex carcinoma. Late pulmonary metastasis of resected adrenal cortex carcinoma].

Authors:  M A Weber; S Delorme
Journal:  Radiologe       Date:  2002-03       Impact factor: 0.635

2.  Andrenocortical carcinomas: twelve-year prospective experience.

Authors:  Libuse Tauchmanovà; Annamaria Colao; Luigi Antonio Marzano; Lucianna Sparano; Luigi Camera; Annalisa Rossi; Giovanna Palmieri; Ettore Marzano; Marco Salvatore; Guido Pettinato; Gaetano Lombardi; Riccardo Rossi
Journal:  World J Surg       Date:  2004-09       Impact factor: 3.352

Review 3.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

4.  Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation.

Authors:  E K Pivnick; W L Furman; G V Velagaleti; J J Jenkins; N A Chase; R C Ribeiro
Journal:  J Med Genet       Date:  1998-04       Impact factor: 6.318

5.  Reciprocal changes in the expression of transcription factors GATA-4 and GATA-6 accompany adrenocortical tumorigenesis in mice and humans.

Authors:  S Kiiveri; S Siltanen; N Rahman; M Bielinska; V P Lehto; I T Huhtaniemi; L J Muglia; D B Wilson; M Heikinheimo
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

6.  Therapy of adrenocortical cancer: present and future.

Authors:  Daniela F Maluf; Brás H de Oliveira; Enzo Lalli
Journal:  Am J Cancer Res       Date:  2010-12-07       Impact factor: 6.166

7.  Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma.

Authors:  Javier Valero-Elizondo; Yuhree Kim; Jason D Prescott; Georgios A Margonis; Thuy B Tran; Lauren M Postlewait; Shishir K Maithel; Tracy S Wang; Jason A Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; George A Poultsides; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-08-19       Impact factor: 3.452

8.  A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis.

Authors:  Emil Lou; Jeremy Goodwin; David N Howell; John Hicks; L Brett Caram
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

9.  Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.

Authors:  Lauren M Postlewait; Cecilia G Ethun; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel
Journal:  J Am Coll Surg       Date:  2015-12-21       Impact factor: 6.113

10.  Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases.

Authors:  Bradford J Wood; Jame Abraham; Julia L Hvizda; H Richard Alexander; Tito Fojo
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.